Stock Scorer

Alnylam Pharmaceuticals Inc (ALNY) · DCF calculator

What is a Alnylam Pharmaceuticals share worth today if its free cash flow keeps growing and the market keeps paying the multiple it has paid? Every starting value below comes from Alnylam Pharmaceuticals's own filings and price history. Change any of them; nothing here is a forecast or advice.

Price today
231.83
USD, close of 2026-10-13
Fair value today
151.17
-34.8% against the price
Price in 5 years
243.47
+5.0% from today
Yearly return
1.0%
if bought at today's price

Assumptions

465.38M
Last twelve months to 2025-12-31, in USD.
%
No four-year history to read a rate from; the default is 5%.
%
Each year the rate is this much lower than the year before.
×
P/FCF at the end: its own five-year median is 108.1×, today 66.5×. The default is the lower.
%
A year. Over the last five years: +3.03% a year. Negative is a buyback.
%
The discount rate: what a year of waiting has to earn.

Free cash flow, as filed and projected

As filed, trailing twelve monthsProjected
YearGrowthFree cash flow
15.0%488.65M
24.5%510.64M
34.1%531.32M
43.6%550.69M
53.3%568.75M

How it is worked out

The figure is grown for each year of the horizon at a rate that fades, the multiple puts a market value on the last year's figure, and that value is divided over the share count as it will be by then. What that future price is worth today is it discounted at the return you want.

growth in year n = g × (1 − fade)n−1 figure in year n = figure in year n−1 × (1 + growth in year n) future price = figure in year N × multiple ÷ (shares today × (1 + share change)N) fair value = future price ÷ (1 + return wanted)N

The starting values are Alnylam Pharmaceuticals's own: the latest twelve months of the figure as filed, what it actually grew at over four years, the company's own five-year median multiple of it or today's if that is lower, and what its share count actually did. A model this simple is only as good as the assumptions put into it, and the most important one -- that the business keeps growing -- is the one no filing can tell you.

Alnylam Pharmaceuticals's scores and multiples ›  ·  Every filed figure ›